Laurel Wealth Advisors (California)’s Teva Pharmaceuticals TEVA Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,490	Closed	-$481K	–	351
2017 Q2	$481K	Sell	14,490 -1,245	-8%	-$38.5K	0.17%	155
2017 Q1	$504K	Sell	15,735 -2,876	-15%	-$98.1K	0.19%	132
2016 Q4	$674K	Sell	18,611 -5,957	-24%	-$238K	0.3%	96
2016 Q3	$1.13M	Sell	24,568 -65	-0.3%	-$3.39K	0.53%	58
2016 Q2	$1.24M	Buy	24,633 +3,368	+16%	+$179K	0.59%	43
2016 Q1	$1.14M	Buy	21,265 +12,857	+153%	+$754K	0.57%	48
2015 Q4	$552K	Buy	+8,408	New	+$520K	0.29%	98

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Laurel Wealth Advisors (California)'s TEVA Position: Q3 2017 in Review

Laurel Wealth Advisors (California) sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 14,490 shares — an estimated $481K sold.

Laurel Wealth Advisors (California) first reported a position in TEVA in Q4 2015 and held it in 7 quarters. The position peaked at $1.24M in Q2 2016. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Laurel Wealth Advisors (California) reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Laurel Wealth Advisors (California) sold 14,490 Teva Pharmaceuticals shares in Q3 2017, an estimated $481K.
Laurel Wealth Advisors (California) first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 7 quarters.
Laurel Wealth Advisors (California)'s Teva Pharmaceuticals position peaked at $1.24M in Q2 2016.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q3 2017, filed 14 Nov 2017.